SAN DIEGO, Sept. 5, 2017
/PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec" or the
"Company" (NASDAQ: ONCS)), a company developing DNA-based
intratumoral cancer immunotherapies, today announced the
appointment of Annalisa
Jenkins, MBBS, FRCP, CEO of Dimension Therapeutics, Inc.
(NASDAQ: DMTX), to its Board of Directors. Dr. Jenkins brings over
25 years of global industry experience to OncoSec's Board of
Directors with a wealth of knowledge in advancing programs from
scientific research through clinical development, regulatory
approval and into healthcare systems globally. Her election to the
Company's Board is effective immediately.
"We are very pleased to have Dr. Jenkins join our Board as we
believe her international biopharma drug development experience
will be an asset to OncoSec as we advance our lead melanoma program
and pursue collaborations with other industry leaders in oncology,"
said Punit Dhillon, President and
CEO of OncoSec. "Drawing on her years of experience in the
biopharma industry, we believe Dr. Jenkins will provide new
insights to our technology and business priorities as we continue
to advance our broad clinical portfolio and achieve future growth
objectives."
"I believe OncoSec's clinical program for ImmunoPulse® IL-12 can
have a significant impact on how we approach cancer care by
addressing a significant unmet need for melanoma patients that do
not currently respond to anti-PD-1 treatments. In addition, I'm
impressed with the Company's commitment to advancing its innovative
drug development approach, putting science and patients at the core
of its mission," said Dr. Jenkins. "I look forward to contributing
to the Company's advancement of its promising product candidates
through clinical development."
Prior to Dimension Therapeutics, Dr. Jenkins served as Executive
Vice President and Head of Global Research and Development for
Merck Serono, a global division of Merck KGaA focused on
biopharmaceuticals. She also led Global Medical Affairs and Quality
at Merck Serono and was a member of its Pharmaceutical Executive
Committee. Dr. Jenkins also had a nearly 15-year career at
Bristol-Myers Squibb, attaining the role of Senior Vice President
and Head of Global Medical Affairs. She began her career as a
Medical Officer with the British Royal Navy during the Gulf
conflict, rising to the rank of Surgeon Lieutenant Commander. Dr.
Jenkins received an MBBS in Medicine from St. Bartholomew's
Hospital in the University of London and trained in cardiovascular medicine
in the National Health Service (U.K.).
Currently, Dr. Jenkins serves as a director for several
companies including: Ardelyx, Inc., Biothera Pharmaceutical Inc.,
iOX Therapeutics Limited, MedCity and Vium. She also is a committee
member of the Science Board to the U.S. Food and Drug
Administration, serves on the Board of the Center for Talent
Innovation (U.K.) and is on the Advisory Panel of the Healthcare
Businesswomen's Association.
About OncoSec Medical Incorporated
OncoSec is a
biotechnology company developing DNA-based intratumoral
immunotherapies with an investigational technology, ImmunoPulse®,
for the treatment of cancer. ImmunoPulse® is designed to
enhance the local delivery and uptake of DNA-based immune-targeting
agents, such as IL-12. In Phase I and II clinical trials,
ImmunoPulse® IL-12 has demonstrated a favorable safety profile
and evidence of anti-tumor activity in the treatment of various
solid tumors and has shown the potential to reach beyond the site
of local treatment to initiate a systemic immune response.
ImmunoPulse® IL-12, OncoSec's lead program, is currently in
clinical development for metastatic melanoma and triple-negative
breast cancer. The program's current focus is on the significant
unmet medical need in patients with melanoma who are refractory or
non-responsive to anti-PD-1/PD-L1 therapies. In addition to
ImmunoPulse® IL-12, the Company is also identifying and
developing new immune-targeting agents for use with the
ImmunoPulse® platform. For more information, please
visit www.oncosec.com.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains "forward-looking
statements" within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995. Forward-looking statements can be
identified by words such as "can," "may," "will," "suggest," "look
forward to," "potential," "understand," and similar references to
future periods.
Forward-looking statements are neither historical facts nor
assurances of future performance. Instead, they are based on
management's current preliminary expectations and are subject to
risks and uncertainties, which may cause our results to differ
materially and adversely from the statements contained herein.
Potential risks and uncertainties that could cause actual results
to differ from those predicted include, among others, the
following: uncertainties inherent in pre-clinical studies and
clinical trials, such as the ability to enroll patients in clinical
trials and the risk of adverse events; unexpected new data, safety
and technical issues; our ability to raise additional funding
necessary to fund continued operations; and the other factors
discussed in OncoSec's filings with the Securities and Exchange
Commission.
Undue reliance should not be placed on forward-looking
statements, which speak only as of the date they are made. OncoSec
disclaims any obligation to update any forward-looking statements
to reflect new information, events or circumstances after the date
they are made, or to reflect the occurrence of unanticipated
events.
CONTACT:
Investor Relations
OncoSec Medical Incorporated
855-662-6732
investors@oncosec.com
Media Relations
OncoSec Medical Incorporated
855-662-6732
media@oncosec.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/oncosec-appoints-industry-veteran-annalisa-jenkins-mbbs-frcp-to-board-of-directors-300513508.html
SOURCE OncoSec Medical Incorporated
